Old Web
English
Sign In
Acemap
>
authorDetail
>
Mark Agius
Mark Agius
Barrow Neurological Institute
Multiple sclerosis
Adverse effect
Medicine
Placebo
Inebilizumab
2
Papers
69
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study:
2019
Multiple Sclerosis Journal
Mark Agius
Gabriela Kłodowska-Duda
Maciej Maciejowski
Andrzej Potemkowski
Jing Li
Kaushik Patra
Jacob Wesley
Soraya Madani
Gerard Barron
Eliezer Katz
Armando Flor
Show All
Source
Cite
Save
Citations (69)
Symptomatic Thrombocytopenia After One Dose of Alemtuzumab With Successful Rechallenge (P5.400)
2017
Neurology
Andrea Derlet
Mark Agius
Michelle Apperson
Show All
Source
Cite
Save
Citations (0)
1